Merck & Co., Inc.
corporate_fare Company Profile
Merck & Co., Inc. (NYSE:MRK) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 60 items for MRK at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-30, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for MRK spans 10-Q, 8-K.
Recent high-impact activity:
- Merck's Tulisokibart Hits Primary Endpoint in Phase 2b Hidradenitis Suppurativa Trial
- Merck Pays $400M Upfront for Global Rights to Preclinical KRAS G12D Inhibitor
- Merck Pulls U.S. Filing for Lung Cancer Drug After FDA Rejects Data
- FDA Approves Belzutifan-Lenvatinib Combo for Advanced Kidney Cancer
- Merck's Remigromig Hits Primary Endpoint in Pivotal DME Trial, First Novel Mechanism in 20 Years
Financial Snapshot
Short Interest & Short Volume
4.23 days to coverFINRA reported short interest of 34,430,712 shares in MRK as of the September 15, 2026 settlement, a 13.7% increase from the prior period — about 4.2 days to cover at its recent average daily volume. On October 8, 2026, 37.7% of MRK volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for MRK, detected from its recent SEC filings · based on capital-structure filings through 2026-05-20.
Debt Offering Finalized · Refinancing Acquisition Debt
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →